Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 6

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 6
---

    $4,077,560  
     22,764,764  
    $38,023,784  
     5,845  
    $   1  
    $1,032,125  
    $(43,089,821) 
    $(42,057,695)
  
    Stock based compensation expense 
     -  
     -  
     -  
     -  
     -  
     -  
     4,431  
     -  
     4,431 
  
    Net loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (572,211) 
     (572,211)
  
    Balance at February 13, 2024 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     5,845  
    $1  
    $1,036,556  
    $(43,662,032) 
    $(42,625,475)

See accompanying notes to the condensed consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8, 2025

3

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

    For the 
Three 
Months 
ended 
March 31, 
2025  
    For the 
Period from 
February 14, 
2024 
through 
March 31, 
2024  
    For the 
Period from 
January 1, 
2024 
through 
February 13, 
2024 

    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Cash flows from operating activities: 

    Net loss 
    $(5,105,931) 
    $(1,727,483) 
    $(572,211)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Gain from settlement of liabilities with vendors 
     -  
     (141,888) 
     - 
  
    Depreciation expense